Original Contributions |
From the Atherosclerosis Research Unit, Department of Medicine (B.H.C., J.P.S., K.H.), the Department of Pediatrics (F.F.), and the Clinical Research Center (B.H.S.C.), University of Alabama at Birmingham; and the H.E. Moore Heart Research Foundation, University of Illinois, Champaign (B.E.D.).
Correspondence to Byung Hong Chung, PhD, Atherosclerosis Research Unit, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294. E-mail Chung{at}aru.dom.uab.edu
AbstractTo investigate the role of
various lipoproteins in plasma to promote cholesterol
efflux from cell membranes, potencies of lipoproteins in normolipidemic
fasting and postprandial (PP) plasmas to accept additional
cholesterol molecules from cell membranes were determined.
We used red blood cells (RBCs) and lipoproteins in fresh blood as
donors and acceptors of cell membrane cholesterol,
respectively. When fresh fasting plasma (n=24) containing active
lecithin:cholesterol acyltransferase (LCAT) and cholesteryl
ester transfer proteins (CETP) was incubated with a 3-fold excess of
autologous RBCs at 37°C for 18 hours, plasma cholesterol
levels increased by 19.6% (38.5±14.2 mg/dL) owing to an exclusive
increase in the CE level. Very low density lipoprotein (VLDL), low
density lipoprotein (LDL), and high density lipoprotein (HDL) fractions
retained 48.1%, 26.3%, and 25.6% of the net cholesterol
mass increase in fasting plasma, resulting in 91%, 8%, and 21%
increases in their cholesterol contents, respectively. The
PP plasma was 1.3-fold more potent than fasting plasma in promoting
cholesterol efflux from RBCs by associating excess
cholesterol with chylomicrons, resulting in a 356%
increase in the cholesterol content of chylomicrons. These
increases in lipoprotein cholesterol content indicate that
chylomicrons were about 3.9x, 44x, and 17x more potent than fasting
VLDL, LDL, and HDL, respectively, in accepting additional
cholesterol molecules released from RBCs. The capacity of
PP plasma to promote cholesterol efflux from RBCs was
significantly correlated with plasma cholesterol levels
(r=0.60, P<0.005),
triglycerides (r=0.68,
P<0.001), chylomicrons (r=0.90,
P<0.001), VLDL (r=0.65,
P<0.001), and LDL (r=0.47,
P<0.025) but not with the levels of HDL
(r=-0.34, P<0.20). In fasting plasma
containing a low level of VLDL and HDL, isolated chylomicrons
supplemented to the plasma were
9x more potent than HDL in boosting
the capacity of plasma to promote cholesterol efflux from
RBCs. This study indicates that chylomicrons in PP plasma are the most
potent ultimate acceptors of cholesterol released from cell
membranes and that a low HDL level is not a factor that limits the
ability of PP plasma to promote cholesterol efflux from
cell membranes. Our data obtained from an in vitro system suggest that
PP chylomicrons may play a major role in promoting reverse
cholesterol transport in vivo, since the transfer of
cholesterol from cell membranes to chylomicrons will lead
to the rapid removal of this cholesterol by the liver. HDL
in vivo may promote reverse cholesterol transport by
enhancing the rapid removal of chylomicrons from the circulation, since
the rate of clearance of chylomicrons is positively correlated with the
HDL level in plasma.
Key Words: chylomicrons HDL lecithin:cholesterol acyltransferase cholesteryl ester transfer proteins reverse cholesterol transport
This article has been cited by other articles:
![]() |
A. H.E.M. Klerkx, K. E. Harchaoui, W. A. van der Steeg, S. M. Boekholdt, E. S.G. Stroes, J. J.P. Kastelein, and J. A. Kuivenhoven Cholesteryl Ester Transfer Protein (CETP) Inhibition Beyond Raising High-Density Lipoprotein Cholesterol Levels: Pathways by Which Modulation of CETP Activity May Alter Atherogenesis Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 706 - 715. [Abstract] [Full Text] [PDF] |
||||
![]() |
B.-H. Chung, B. S. Cho, P. Liang, S. Doran, L. Osterlund, R. A Oster, B. Darnell, and F. Franklin Contribution of postprandial lipemia to the dietary fat-mediated changes in endogenous lipoprotein-cholesterol concentrations in humans Am. J. Clinical Nutrition, November 1, 2004; 80(5): 1145 - 1158. [Abstract] [Full Text] [PDF] |
||||
![]() |
B.-H. Chung, P. Liang, S. Doran, B. H. S. Cho, and F. Franklin Postprandial chylomicrons: potent vehicles for transporting cholesterol from endogenous LDL+HDL and cell membranes to the liver via LCAT and CETP J. Lipid Res., July 1, 2004; 45(7): 1242 - 1255. [Abstract] [Full Text] [PDF] |
||||
![]() |
B.-H. Chung, S. Doran, P. Liang, L. Osterlund, B. S. Cho, R. A Oster, B. Darnell, and F. Franklin Alcohol-mediated enhancement of postprandial lipemia: a contributing factor to an increase in plasma HDL and a decrease in risk of cardiovascular disease Am. J. Clinical Nutrition, September 1, 2003; 78(3): 391 - 399. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Guerin, P. Egger, C. Soudant, W. Le Goff, A. van Tol, R. Dupuis, and M. J. Chapman Cholesteryl ester flux from HDL to VLDL-1 is preferentially enhanced in type IIB hyperlipidemia in the postprandial state J. Lipid Res., October 1, 2002; 43(10): 1652 - 1660. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Christian, H.-S. Byun, N. Zhong, M. Wanunu, T. Marti, A. Fürer, F. Diederich, R. Bittman, and G. H. Rothblat Comparison of the capacity of {beta}-cyclodextrin derivatives and cyclophanes to shuttle cholesterol between cells and serum lipoproteins J. Lipid Res., August 1, 1999; 40(8): 1475 - 1482. [Abstract] [Full Text] |
||||
![]() |
L. F. Tinker, E. J Parks, S. R. Behr, B. O. Schneeman, and P. A. Davis (n-3) Fatty Acid Supplementation in Moderately Hypertriglyceridemic Adults Changes Postprandial Lipid and Apolipoprotein B Responses to a Standardized Test Meal J. Nutr., June 1, 1999; 129(6): 1126 - 1134. [Abstract] [Full Text] |
||||
![]() |
G. H. Rothblat, M. de la Llera-Moya, V. Atger, G. Kellner-Weibel, D. L. Williams, and M. C. Phillips Cell cholesterol efflux: integration of old and new observations provides new insights J. Lipid Res., May 1, 1999; 40(5): 781 - 796. [Abstract] [Full Text] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1998 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |